Menefee’s resignation was triggered by the Texas Constitution, which bars local officials from seeking an office other than ...
Genentech (S. San Francisco, CA) has announced disappointing phase II trial results of its anti-CD18 monoclonal antibodies in treating heart attacks. Preliminary analysis of the data in June ...